Vincristine Sulfate
FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Vinca alkaloids and analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Micafungin SodiumExisting use: Candidiasis52.4% AI-predicted activityagainst E. coli50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm52.3% AI-predicted activityagainst E. coli50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- FinerenoneExisting use: Cardiovascular disease, Chronic kidney disease, Type 2 diabetes mellitus52.2% AI-predicted activityagainst E. coli50+ registered studies
- Bromocriptine MesylateExisting use: Acromegaly, Adenoma, Hyperprolactinemia and 4 more52.2% AI-predicted activityagainst E. coli50+ registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma52.0% AI-predicted activityagainst E. coli50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more52.0% AI-predicted activityagainst E. coli22 registered studies
- PimecrolimusExisting use: Atopic eczema, Eczematoid dermatitis51.9% AI-predicted activityagainst E. coli50+ registered studies
- Quizartinib DihydrochlorideExisting use: Acute myeloid leukemia, Myeloid leukemia51.8% AI-predicted activityagainst E. coli4 registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.6% AI-predicted activityagainst E. coli50+ registered studies
- Dabigatran Etexilate MesylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 5 more51.4% AI-predicted activityagainst E. coli14 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
NCT05040906 · start 2020-10-13
Registered record
- Registry ID
- NCT05040906
- Conditions
- Recruiting
- Interventions
- H02+CHOP; Rituxan +CHOP
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2020-10-13
- Completion
- 2023-12-31
- Enrolment
- 416
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecruitingInterventionH02+CHOP; Rituxan +CHOPPhasePhase 3Registry statusUnknownThalidomide Combined With R-CHOP in Newly Diagnosed,Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
NCT03318835 · start 2017-08-22
Registered record
- Registry ID
- NCT03318835
- Conditions
- Thalidomide
- Interventions
- Thalidomide combined with R-CHOP; R-CHOP
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2017-08-22
- Completion
- 2020-08-22
- Enrolment
- 162
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionThalidomideInterventionThalidomide combined with R-CHOP; R-CHOPPhasePhase 3Registry statusUnknownSafety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
NCT03023878 · start 2017-03-13
Registered record
- Registry ID
- NCT03023878
- Conditions
- High-risk Diffuse Large B-Cell Lymphoma
- Interventions
- Blinatumomab; Investigator's Choice Chemotherapy; Dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2017-03-13
- Completion
- 2019-10-28
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHigh-risk Diffuse Large B-Cell LymphomaInterventionBlinatumomab; Investigator's Choice Chemotherapy; DexamethasonePhasePhase 2Registry statusCompletedVolasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02861040 · start 2016-08
Registered record
- Registry ID
- NCT02861040
- Conditions
- Recurrent Adult Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic Leukemia
- Interventions
- Laboratory Biomarker Analysis; Pharmacological Study; Vincristine Sulfate Liposome; Volasertib
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Withdrawn
- Start
- 2016-08
- Completion
- Not recorded
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRecurrent Adult Acute Lymphoblastic Leukemia; Refractory Adult Acute Lymphoblastic LeukemiaInterventionLaboratory Biomarker Analysis; Pharmacological Study; Vincristine Sulfate Liposome; VolasertibPhasePhase 1Registry statusWithdrawnTreatment for Classical Hodgkin Lymphoma in Children and Adolescents
NCT02797717 · start 2015-11
Registered record
- Registry ID
- NCT02797717
- Conditions
- Classical Hodgkins Lymphoma in Children and Adolescents.
- Interventions
- Radiotherapy:; Vincristine; Etoposide; Prednisone; Doxorubicin; Dacarbazine; Cyclophosphamide
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2015-11
- Completion
- 2027-12
- Enrolment
- 2,200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionClassical Hodgkins Lymphoma in Children and Adolescents.InterventionRadiotherapy:; Vincristine; Etoposide; Prednisone +3 morePhaseNot applicableRegistry statusRecruitingStudy of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
NCT02356159 · start 2015-09-24
Registered record
- Registry ID
- NCT02356159
- Conditions
- Myelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia; Multiple Myeloma
- Interventions
- Rituximab; Conditioning chemotherapy; TMS; FLAG; EPOCH-F; Hematopoietic stem cell transplant; Palifermin; Acetaminophen; Diphenhydramine; Prednisone; Epinephrine; IV Saline; ECG; ECHO; MUGA; DEXA; CT chest; PET; MRI; BM aspirate; BM biopsy; Lumbar puncture
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2015-09-24
- Completion
- 2025-03-25
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyelodysplastic Syndromes; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Acute Leukemia +1 moreInterventionRituximab; Conditioning chemotherapy; TMS; FLAG +18 morePhasePhase 1 / Phase 2Registry statusCompletedCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222 · start 2014-05-19
Registered record
- Registry ID
- NCT02003222
- Conditions
- Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Cytarabine; Daunorubicin; Daunorubicin Hydrochloride; Dexamethasone; Etoposide; Leucovorin Calcium; Lumbar Puncture; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Rituximab; Vincristine; Vincristine Sulfate; X-Ray Imaging
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Active not recruiting
- Start
- 2014-05-19
- Completion
- 2027-02-25
- Enrolment
- 488
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeInterventionAllogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration +17 morePhasePhase 3Registry statusActive not recruitingA Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT01463852 · start 2012-10
Registered record
- Registry ID
- NCT01463852
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- vincristine
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2012-10
- Completion
- 2014-12
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Lymphocytic Leukemia (CLL)InterventionvincristinePhaseEarly phase 1Registry statusTerminatedMetformin in Children With Relapsed or Refractory Solid Tumors
NCT01528046 · start 2012-09-24
Registered record
- Registry ID
- NCT01528046
- Conditions
- Solid Tumors; Primary Brain Tumors
- Interventions
- Vincristine; Irinotecan; Temozolomide; Metformin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-09-24
- Completion
- 2020-02-03
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSolid Tumors; Primary Brain TumorsInterventionVincristine; Irinotecan; Temozolomide; MetforminPhasePhase 1Registry statusCompletedCyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
NCT01313884 · start 2011-05
Registered record
- Registry ID
- NCT01313884
- Conditions
- Bone Cancer; Ewing's Sarcoma
- Interventions
- Irinotecan; Vincristine; Temozolomide; Doxorubicin; Cytoxan; Pegfilgrastim
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2011-05
- Completion
- 2014-07
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBone Cancer; Ewing's SarcomaInterventionIrinotecan; Vincristine; Temozolomide; Doxorubicin +2 morePhasePhase 2Registry statusTerminatedA Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
NCT01309789 · start 2011-02
Registered record
- Registry ID
- NCT01309789
- Conditions
- Lymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cell
- Interventions
- brentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone; cyclophosphamide; doxorubicin; doxorubicin; prednisone; vincristine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2017-02-28
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphoma, Large-Cell, Anaplastic; Lymphoma, NK-cell; Lymphoma, T-cellInterventionbrentuximab vedotin; cyclophosphamide; brentuximab vedotin; prednisone +5 morePhasePhase 1Registry statusCompletedClofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL
NCT01228331 · start 2010-10
Registered record
- Registry ID
- NCT01228331
- Conditions
- Leukemia
- Interventions
- Amsacrine; Clofarabine; Cyclophosphamide; Cytarabine; Daunorubicin hydrochloride; Dexamethasone; Doxorubicin hydrochloride; Etoposide phosphate; Mercaptopurine; Methotrexate; Methylprednisolone; Pegaspargase; Thioguanine; Vincristine sulfate; Whole-brain radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2010-10
- Completion
- 2024-11-20
- Enrolment
- 745
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventionAmsacrine; Clofarabine; Cyclophosphamide; Cytarabine +11 morePhasePhase 2 / Phase 3Registry statusCompletedInternational Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
NCT01117441 · start 2010-06
Registered record
- Registry ID
- NCT01117441
- Conditions
- Leukemia
- Interventions
- PEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; vindesine; daunoxome; fludarabine; Radiation Therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-06
- Completion
- 2021-12-31
- Enrolment
- 6,136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventionPEG-L-asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride +13 morePhasePhase 3Registry statusCompletedIntercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
NCT01014767 · start 2009-11
Registered record
- Registry ID
- NCT01014767
- Conditions
- Brain Cancer; Choroid Plexus Tumors
- Interventions
- Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Irinotecan; Leucovorin; Methotrexate; Temozolomide; Vincristine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2009-11
- Completion
- 2014-01
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain Cancer; Choroid Plexus TumorsInterventionCarboplatin; Cisplatin; Cyclophosphamide; Dactinomycin +7 morePhasePhase 3Registry statusTerminatedPre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
NCT00882206 · start 2009-04
Registered record
- Registry ID
- NCT00882206
- Conditions
- Leukemia; Lymphoma
- Interventions
- cytarabine; decitabine; doxorubicin hydrochloride; imatinib mesylate; methotrexate; pegaspargase; prednisone; vincristine sulfate; vorinostat
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2009-04
- Completion
- 2013-01
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; LymphomaInterventioncytarabine; decitabine; doxorubicin hydrochloride; imatinib mesylate +5 morePhasePhase 2Registry statusTerminated